ZIFFPAGE TITLEBy Deborah Gage | Posted 2005-12-06 Email Print
WEBINAR: On-demand webcast
Next-Generation Applications Require the Power and Performance of Next-Generation Workstations REGISTER >
The drug maker's best-seller has some nasty side effects. A voice recognition system helps patients, doctors and pharmacists manage the risk.Celgene Base Case">
Celgene Base CaseHeadquarters: 86 Morris Ave., Summit, NJ 07901
Phone: (908) 673-9000
Business: Discovering, developing and commercializing pharmaceuticals
Information Technology Director: Steve Lerner
Financials in 2004: $377.5 million in revenue; $52.8 million in net income.
Challenge: To put in place an information system that will help prevent drug side effects such as birth defects, miscarriages and blood clots.
- Boost revenue by 39% to $525 million in 2005, from $377.5 million in 2004.
- Generate $400 million in sales of Thalomid in 2005, an increase of 29.6% from $308.6 million in 2004.
- Raise R&D spending by 24.3% to $200 million in 2005, from $160.9 million the previous year.
- Increase selling, general and administrative expenses to $175 million in 2005, from $114.2 million in 2004, to support the launch of Revlimid.